Cargando…

Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets

OBJECTIVE: Investigate a combination of two clinically tested drugs, the NR2B antagonist Radiprodil and the A(2A) antagonist Tozadenant in the MPTP-treated marmoset model of Parkinson’s Disease (PD). BACKGROUND: In PD, there remains a need for the development of non-dopaminergic drugs to effectively...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michel, Anne, Nicolas, Jean-Marie, Rose, Sarah, Jackson, Michael, Colman, Peter, Briône, Willy, Sciberras, David, Muglia, Pierandrea, Scheller, Dieter K., Citron, Martin, Downey, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576667/ https://www.ncbi.nlm.nih.gov/pubmed/28854243 http://dx.doi.org/10.1371/journal.pone.0182887

Ejemplares similares

Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndrome
por: Auvin, Stéphane, et al.
Publicado: (2020)

The Antiparkinsonian and Antidyskinetic Mechanisms of Mucuna pruriens in the MPTP-Treated Nonhuman Primate
por: Lieu, Christopher A., et al.
Publicado: (2012)

Altered detrusor contractility in MPTP-treated common marmosets with bladder hyperreflexia
por: Pritchard, Sara, et al.
Publicado: (2017)

A pharmacokinetic study of radiprodil oral suspension in healthy adults comparing conventional venous blood sampling with two microsampling techniques
por: Sciberras, David, et al.
Publicado: (2019)

Antipsychotics dosage and antiparkinsonian prescriptions
por: Acquaviva, Eric, et al.
Publicado: (2007)

Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs
por: Silva, Sara, et al.
Publicado: (2021)

The selective 5-HT(1A) receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets
por: Fisher, Ria, et al.
Publicado: (2020)

A STUDY OF PROPHYLACTIC VALUE OF ANTIPARKINSONIAN DRUG
por: Behere, P.B., et al.
Publicado: (1983)

PET Analysis of Dopaminergic Neurodegeneration in Relation to Immobility in the MPTP-Treated Common Marmoset, a Model for Parkinson’s Disease
por: Ando, Kiyoshi, et al.
Publicado: (2012)

Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder
por: Massari, Caio M., et al.
Publicado: (2017)

Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems
por: Paccione, Nicola, et al.
Publicado: (2022)

The Monoamine Re-Uptake Inhibitor UWA-101 Improves Motor Fluctuations in the MPTP-Lesioned Common Marmoset
por: Huot, Philippe, et al.
Publicado: (2012)

Trends in Antiparkinsonian Medication Use in New Zealand: 1995–2011
por: Pitcher, T. L., et al.
Publicado: (2014)

Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication
por: Chung, Jae Woo, et al.
Publicado: (2017)

Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson’s disease
por: Taguchi, Soutarou, et al.
Publicado: (2021)

Orthostatic Hypotension and Antiparkinsonian Drugs: A Systematic Review and Meta-analysis
por: Nimmons, Danielle, et al.
Publicado: (2021)

Antiparkinsonian medication masks motor signal progression in de novo patients()
por: Brzezicki, Maksymilian A., et al.
Publicado: (2023)

Quantitative Analysis of Tozadenant Using Liquid Chromatography-Mass Spectrometric Method in Rat Plasma and Its Human Pharmacokinetics Prediction Using Physiologically Based Pharmacokinetic Modeling
por: Lee, Byeong ill, et al.
Publicado: (2019)

Deciphering the Actions of Antiparkinsonian and Antipsychotic Drugs on cAMP/DARPP-32 Signaling
por: Bonito-Oliva, Alessandra, et al.
Publicado: (2011)

Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications
por: Miguelez, Cristina, et al.
Publicado: (2017)

Predictive Factors of Antiparkinsonian Drug Reduction after Subthalamic Stimulation for Parkinson’s Disease
por: SAMURA, Kazuhiro, et al.
Publicado: (2019)

Time until modification of antiparkinsonian therapy in a group of patients from Colombia
por: Valencia-Vásquez, Aníbal, et al.
Publicado: (2023)

Unprecedented Therapeutic Potential with a Combination of A(2A)/NR2B Receptor Antagonists as Observed in the 6-OHDA Lesioned Rat Model of Parkinson's Disease
por: Michel, Anne, et al.
Publicado: (2014)

Rapid preparation process of antiparkinsonian drug Mucuna pruriens silver nanoparticle by bioreduction and their characterization
por: Arulkumar, Subramanian, et al.
Publicado: (2010)

1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents
por: Ortíz de Zárate, Ana, et al.
Publicado: (2021)

The Common Marmoset: A Highly Translatable Small Nonhuman Primate Model of Aging
por: Colman, Ricki
Publicado: (2021)

c-Abl Inhibition Exerts Symptomatic Antiparkinsonian Effects Through a Striatal Postsynaptic Mechanism
por: Zhou, Yu, et al.
Publicado: (2018)

LUHMES Cells: Phenotype Refinement and Development of an MPP(+)-Based Test System for Screening Antiparkinsonian Drugs
por: Beliakov, Sergei V., et al.
Publicado: (2023)

Motor Improvement-Related Regional Cerebral Blood Flow Changes in Parkinson's Disease in Response to Antiparkinsonian Drugs
por: Taguchi, Soutarou, et al.
Publicado: (2019)

The MPTP Story
por: Langston, J. William
Publicado: (2017)

Fathering style influences health outcome in common marmoset (Callithrix jacchus) offspring
por: Ziegler, Toni E., et al.
Publicado: (2017)

The 5-HT(2A) Receptor Antagonist M100907 Produces Antiparkinsonian Effects and Decreases Striatal Glutamate
por: Ansah, Twum A., et al.
Publicado: (2011)

The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database
por: Johannes, Catherine B., et al.
Publicado: (2022)

Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson’s disease
por: Modo, Michel, et al.
Publicado: (2017)

Blockade of fast A-type and TEA-sensitive potassium channels provide an antiparkinsonian effect in a 6-OHDA animal model
por: Haghdoost-Yazdi, Hashem, et al.
Publicado: (2017)

Marmoset prosociality is intentional
por: Burkart, Judith M., et al.
Publicado: (2020)

Viral Vector-Based Dissection of Marmoset GFAP Promoter in Mouse and Marmoset Brains
por: Shinohara, Yoichiro, et al.
Publicado: (2016)

Diet, digestion and energy intake in captive common marmosets (Callithrix jacchus): research and management implications
por: Power, Michael L., et al.
Publicado: (2019)

Functional Cardiovascular Characterization of the Common Marmoset (Callithrix jacchus)
por: Klösener, Lina, et al.
Publicado: (2023)

Coumarin analogue 3-methyl-7H-furo[3,2-g]chromen-7-one as a possible antiparkinsonian agent
por: Olaya, María del Pilar, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tel2cf2soo8vmo75boc0361k08